For years, tanning beds, booths, and sunlamps have been linked to an increased risk of skin cancer, yet the number of people using tanning devices continues to rise. An alarming new study shows that indoor tanning costs the US $343 million a year in medical bills, highlighting the severity of this growing health issue.
MD Anderson has placed a much-ballyhooed ‘Watson for cancer’ product it was developing with IBM on hold — and is looking for a new partner.
Since launching in 2011, Silicon Valley healthcare startup Sano Intelligence has kept a low profile. Despite raising $20 million in venture capital, the company founded by ex-Bain Capital analyst and bioengineering grad Ashwin Pushpala has yet to release its product—a continuous glucose tracker that sticks to a users’ skin and monitors blood through an app. Gizmodo has obtained new details about the device, and how the company intends to market it as a product for “metabolic insight” for non-diabetics, rather than to diabetics who regularly need to track their glucose. The strategy means Sano doesn’t need FDA approval, but doctors and diabetes experts interviewed by Gizmodo question whether the product would have any benefits to non-diabetics at all.